Corcept Therapeutics Incorporated (CORT)

Corcept Therapeutics Incorporated is trading at $103.91, down 3.34% on the session. The 50 day average sits at $115.67 and the 200 day at $72.15, which puts the stock in a uptrend. RSI is at 44.2, which reads as weak, and MACD is bearish crossover. Volume is below average.

The nearest support is around $111.94 with resistance near $117.84, so that band frames the current range. Average daily movement is roughly $5.01, or about 4.8% of the share price, which is what any stop placement has to allow for. The overall health score of 56 out of 100 combines a trend score of 77, momentum of 33 and a risk score of 56.

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.